The Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 6.22 million in 2024 and is expected to reach USD 13.11 million by 2033, growing at a CAGR of 9.77% from 2025 to 2033. Rising awareness of neurodegenerative diseases, coupled with an aging population across the region, is fueling demand for early detection tools. Traditionally, Alzheimer’s diagnosis has relied on expensive and invasive methods such as PET imaging or cerebrospinal fluid (CSF) testing, which are often limited in availability across MEA. Blood-based biomarkers offer a cost-effective, scalable, and minimally invasive alternative, making them particularly attractive in regions with constrained healthcare infrastructure.
As governments prioritize healthcare modernization and invest in early detection programs, adoption of blood biomarker tests is expected to expand. Market growth is also supported by international collaborations, local clinical trials, and the entry of global biotech companies into MEA, further bridging the gap between advanced Western technologies and regional healthcare needs.
Population aging and the regional dementia burden are powerful demand drivers. The Arab world had ~1.33 million people with dementia in 2021, while the WHO estimates 57 million globally (60-70% Alzheimer’s), with most cases in low/middle-income countries-categories that include many MEA markets. In Africa, studies report dementia incidence ~13.3 per 1,000 person-years and wide prevalence ranges (2.3-20%), underscoring unmet diagnostic need. Five reasons this pushes BBMs: (1) growing at-risk 65+ cohorts; (2) earlier detection improves care planning; (3) primary-care-friendly testing expands reach; (4) caregiver and societal burden pressures ministries to act; and (5) health-system KPI shifts toward chronic-disease management. Country snapshots illustrate heterogeneity: Lebanon shows high point prevalence (~828/100k), while the UAE is lower (~652/100k)-but rapid population aging and high health spending can still sustain demand. Together, these epidemiological realities create a durable, multi-year addressable market for AD BBMs.
Capital flows into MEA healthcare expand diagnostic capacity and BBM adoption. Saudi Arabia’s Vision 2030 Health Sector Transformation Program is overhauling delivery models, while 2024 budget updates cite USD 57 billion for health/social development-funds that often translate into new labs, LIMS, and quality programs.
This product will be delivered within 1-3 business days.
As governments prioritize healthcare modernization and invest in early detection programs, adoption of blood biomarker tests is expected to expand. Market growth is also supported by international collaborations, local clinical trials, and the entry of global biotech companies into MEA, further bridging the gap between advanced Western technologies and regional healthcare needs.
Population aging and the regional dementia burden are powerful demand drivers. The Arab world had ~1.33 million people with dementia in 2021, while the WHO estimates 57 million globally (60-70% Alzheimer’s), with most cases in low/middle-income countries-categories that include many MEA markets. In Africa, studies report dementia incidence ~13.3 per 1,000 person-years and wide prevalence ranges (2.3-20%), underscoring unmet diagnostic need. Five reasons this pushes BBMs: (1) growing at-risk 65+ cohorts; (2) earlier detection improves care planning; (3) primary-care-friendly testing expands reach; (4) caregiver and societal burden pressures ministries to act; and (5) health-system KPI shifts toward chronic-disease management. Country snapshots illustrate heterogeneity: Lebanon shows high point prevalence (~828/100k), while the UAE is lower (~652/100k)-but rapid population aging and high health spending can still sustain demand. Together, these epidemiological realities create a durable, multi-year addressable market for AD BBMs.
Capital flows into MEA healthcare expand diagnostic capacity and BBM adoption. Saudi Arabia’s Vision 2030 Health Sector Transformation Program is overhauling delivery models, while 2024 budget updates cite USD 57 billion for health/social development-funds that often translate into new labs, LIMS, and quality programs.
MEA Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East & Africa blood-based biomarker for Alzheimer’s disease diagnostics market report based on type, technology, end-use, and country:Type Outlook (Revenue, USD Million, 2021-2033)
- Amyloid-related markers
- Tau-related markers
- Neurodegeneration
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Immunoassays
- Mass spectrometry-based assays
- Next-generation platforms
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Clinical laboratories & hospital labs
- Pharma & biotech
- Academic & research institutes
- Others
Country Outlook (Revenue, USD Million, 2021-2033)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Methodology and Scope
Chapter 2. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Executive Summary
Chapter 3. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Variables, Trends, & Scope
Chapter 4. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
Chapter 5. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Technology Estimates & Trend Analysis
Chapter 6. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market: Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East & Africa Blood-based Biomarker for Alzheimer’s Disease Diagnostics market report include:- F. Hoffmann-La Roche Ltd
- Quanterix
- Fujirebio
- C2N Diagnostics
- Quest Diagnostics Incorporated
- ALZpath
- Bio-Techne
- Alamar Biosciences, Inc.
- Beckman Coulter
